Project Grant R21HL170213
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$122K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This Project Grant award of $602,358, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to assess the contribution of epigenetics to cardiovascular risk in African American women. The project will identify epigenetic biomarkers of cardiovascular disease and its environmental determinants, and evaluate if these biomarkers can contribute to risk prediction assessments. The research will be conducted by the...
This Project Grant award of $804,982, awarded on July 25, 2025 by the National Heart, Lung, and Blood Institute (NHLBI), supports research under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how race, ethnicity, and genetic ancestry contribute to complex traits across diverse human populations in the U.S. The grant leverages data from the Trans-Omics for Precision Medicine (TOPMed) project, which includes whole genome sequencing, RNA-seq expression, metabolomics,...
This $767,579 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to leverage large-scale biobanks to discover and define rare variant effects in hypertrophic cardiomyopathy (HCM). The key objectives are to: Define the contribution and phenotypic manifestations of established HCM disease genes in diverse, non-referral populations. Assess the pathogenicity of candidate HCM genes and establish a platform to evaluate variants of...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...
This Project Grant award of $760,982.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of Texas MD Anderson Cancer Center to investigate the role of the enzyme GFPT2 in radiation-induced cardiovascular disease. The key objectives are to elucidate how radiation-induced telomeric DNA damage and subsequent signaling pathways lead to GFPT2 acetylation and stabilization, thereby promoting glutamate metabolism and...
This federal Project Grant award, totaling $753,813 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to develop novel machine learning techniques for predicting cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The key goals are to use cardiac MRI imaging and genomic data to: 1) Develop a machine learning model to accurately identify CHIP patients and predict their risk...
The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $705,279 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Trustees of Boston University, doing business as Boston University Medical Campus, to investigate the mechanisms by which environmental pollutants impact the cardiovascular system. The 4-year project, starting January 1, 2025, will use a multidisciplinary approach including physiological studies, cellular imaging, RNA-sequencing, and mouse models to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA program 93.837 Cardiovascular Diseases Research is providing $807,948 to support a study on the genetics of left ventricular hypertrophy (LVH) and associated cardiac phenotypes. The primary awardee, The Medical College of Wisconsin, Inc. (MCW), will utilize whole genome sequencing data from the NHLBI TOPMed program to conduct association analyses and identify genetic variants related to LVH....